tipiracil/trifluridine; TAS-102 (Lonsurf)

From Aaushi
Jump to navigation Jump to search

Indications

* improves life-expectancy 7.1 vs. 5.3 months in patients refractory to conventional therapy[1]

Contraindications

Pregnancy category: X :Safety in lactation: -

Monitor

Adverse effects

More general terms

Components

References

  1. 1.0 1.1 1.2 Mayer RJ et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015 May 14; 372:1909 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25970050 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414325
  2. 2.0 2.1 FDA News Release. September 22, 2015 FDA approves new oral medication to treat patients with advanced colorectal cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm

Database